Given the overactive PI3K/AKT/mTOR axis in GBM, the preclinical study for the dual inhibition of AKT with perifisone and mTOR with temsirolimus, has already shown synergistic anti‐tumor effects [120]. The gene discussed is PIK3CA; the disease is neoplasm.